Clinical Trials Search Tool

[FRONTEND] CT Search

ATH-1017 Treatment in Subject with Parkinson’s Disease Dementia or Dementia with Lewy Bodies

Disease/Condition: Parkinson’s Disease Dementia or Dementia with Lewy Bodies (DLB)

Location: Portland

Ages: 40-85

Enrollment Opens: 03-01-2022

Enrollment Closes: TBD

More info »

ATH-1017 for Treatment of Mild to Moderate Alzheimer’s Disease

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 55-85

Enrollment Opens: 12-01-2021

Enrollment Closes: TBD

More info »

A Donanemab Prevention Study in Participants with Alzheimer’s Disease

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 55-80

Enrollment Opens: 01-01-2022

Enrollment Closes: TBD

More info »

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants with Early Alzheimer’s Disease

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 50-85

Enrollment Opens: 04-01-2022

Enrollment Closes: TBD

More info »

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 50-80

Enrollment Opens: 09-01-2021

Enrollment Closes: TBD

More info »

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer’s Disease

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 50-87

Enrollment Opens: 04-01-2022

Enrollment Closes: TBD

More info »

An Observational Study of Aducanumab-avwa in Participants With Alzheimer’s Disease in the US

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 18+

Enrollment Opens: 01-01-2022

Enrollment Closes: TBD

More info »

A Research Study Investigating Semaglutide in People With Early Alzheimer’s Disease

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 55-85

Enrollment Opens: 04-01-2022

Enrollment Closes: TBD

More info »

A trial of oral Semaglutide in patients with early Alzheimer’s Disease (EVOKE)

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 55-85

Enrollment Opens: 01-31-2022

Enrollment Closes: TBD

More info »

A trial of oral Semaglutide in patients with early Alzheimer’s Disease who also exhibit MRI evidence of cerebrovascular disease (EVOKE PLUS)

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 55-65

Enrollment Opens: 01-31-2022

Enrollment Closes: TBD

More info »

AHEAD 3-45 Study: A clinical trial to evaluate the efficacy and safety of treatment with BAN 2401 in patients with pre-clinical Alzheimer’s Disease risk factors

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 50-80

Enrollment Opens: 11/03/2020

Enrollment Closes: TBD

More info »

ATHIRA 0201~A randomized, placebo controlled study of ATH-1017 treatment in patients with mild to moderate Alzheimer’s Disease.

Disease/Condition: Alzheimer’s disease

Location: Portland

Ages: 55-85

Enrollment Opens: 11/18/2020

Enrollment Closes: TBD

More info »

ATH-1017-Treatment in patients with Parkinson’s Disease Dementia or DLB (Dementia with Lewy Bodies)

Disease/Condition: Parkinson’s Disease Dementia or Dementia with Lewy Bodies (DLB)

Location: Portland

Ages: 40-85

Enrollment Opens: 03/21/2022

Enrollment Closes: TBD

More info »

Phase II Diabetic Macular Edema Study

Disease/Condition: Diabetic Macular Edema

Location: Eugene

Ages: 18+

Enrollment Opens: 12-01-2021

Enrollment Closes: TBD

More info »

Phase II Diabetic Macular Edema Study

Disease/Condition: Diabetic Macular Edema

Location: Eugene

Ages: 18+

Enrollment Opens: 12-01-2021

Enrollment Closes: TBD

More info »

Phase 2/3 Diabetic Macular Edema Trial

Disease/Condition: Diabetic Macular Edema

Location: Eugene

Ages: 18-85

Enrollment Opens: 11-01-2021

Enrollment Closes: TBD

More info »

Phase II Geographic Atrophy from Dry Age-Related Macular Degeneration Study

Disease/Condition: Age-Related Macular Degeneration

Location: Eugene

Ages: 55+

Enrollment Opens: 09-01-2021

Enrollment Closes: TBD

More info »

Phase 3 Wet Age-Related Macular Degeneration Study

Disease/Condition: Age-Related Macular Degeneration

Location: Eugene

Ages: 50+

Enrollment Opens: 05-01-2021

Enrollment Closes: TBD

More info »

Phase II Diabetic Macular Edema Study

Disease/Condition: Diabetic Macular Edema

Location: Eugene

Ages: 18+

Enrollment Opens: 12-01-2021

Enrollment Closes: TBD

More info »

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults.

Disease/Condition: SARS-COV-2

Location: Gresham

Ages: 6M – 5 years of age

Enrollment Opens: 04-25-2022

Enrollment Closes: TBD

More info »

A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2 years and above

Enrollment Opens: 11-23-2021

Enrollment Closes: TBD

More info »

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects with Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2 years of age and above

Enrollment Opens: 04-29-2022

Enrollment Closes: TBD

More info »

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Disease/Condition: Bacterial Meningitis, MenABCWY combination vaccine

Location: Gresham

Ages: 11-14 years + 364 days

Enrollment Opens: 02-01-2022

Enrollment Closes: TBD

More info »

A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2-12 years of age

Enrollment Opens: 11-28-2021

Enrollment Closes: TBD

More info »

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2 – 12 years of age

Enrollment Opens: 09-22-2021

Enrollment Closes: TBD

More info »

A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 6-17 years of age and >18

Enrollment Opens: 04-08-2021

Enrollment Closes: TBD

More info »

A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2 years and older

Enrollment Opens: 07-29-2021

Enrollment Closes: TBD

More info »

A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2-5 years of age

Enrollment Opens: 06-30-2021

Enrollment Closes: TBD

More info »

Double-blind, Placebo-controlled and Long-term Study Evaluating the Efficacy and Safety of Prucalopride in Pediatric Subjects with Functional Constipation

Disease/Condition: Functional Constipation

Location: Gresham

Ages: 6 months – 17 years

Enrollment Opens: 07-07-2021

Enrollment Closes: TBD

More info »

A Urine Sample Collection Study in Apparently Healthy Adults and Adults with Chronic, Stable Morbidities

Disease/Condition: Urine Sample Collection Study

Location: Gresham

Ages: 21 – >75

Enrollment Opens: 03-17-2022

Enrollment Closes: TBD

More info »

Clinical Validation of the Healgen Rapid COVID-19 Antigen Test using Subject or Healthcare Provider Collected Nasal Samples for Point-of-Care Use

Disease/Condition: COVID-19 Antigen Test

Location: Gresham

Ages: 2 years of age and older

Enrollment Opens: TBD

Enrollment Closes: TBD

More info »

A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to < 18 years of age

Disease/Condition: SARS-COV-2

Location: Gresham

Ages: 12-18 years of age

Enrollment Opens: 05-30-2022

Enrollment Closes: TBD

More info »

A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Multi-valent Pneumococcal Vaccine, in Healthy Infants in Comparison to PCV13

Disease/Condition: Pneumococcal Vaccine

Location: Gresham

Ages: 6 to 13 weeks of age

Enrollment Opens: 06-15-2022

Enrollment Closes: TBD

More info »

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Disease/Condition: Migraine Headache

Location: Portland

Ages: 18+

Enrollment Opens: 07/21/2021

Enrollment Closes: TBD

More info »

Moderate-to-Severe Psoriasis Study

Disease/Condition: Psoriasis

Location: Portland

Ages: 18+

Enrollment Opens: 02-22-2022

Enrollment Closes: TBD

More info »

Moderate-to-Severe Hidradenitis Suppurativa Study

Disease/Condition: Hidradenitis Suppurativa

Location: Portland

Ages: 18+

Enrollment Opens: 03-02-2022

Enrollment Closes: TBD

More info »

Moderate-to-Severe Eczema for Children

Disease/Condition: Eczema

Location: Portland

Ages: 2-17

Enrollment Opens: 09-22-2021

Enrollment Closes: TBD

More info »

Mild-to-Severe Atopic Dermatitis

Disease/Condition: Eczema

Location: Portland

Ages: 18-75

Enrollment Opens: 01-24-2022

Enrollment Closes: TBD

More info »

Mild-to-Moderate Eczema for Children

Disease/Condition: Eczema

Location: Portland

Ages: 6-17

Enrollment Opens: 03-21-2021

Enrollment Closes: TBD

More info »

Moderate-to-Severe Eczema for Adults

Disease/Condition: Eczema

Location: Portland

Ages: 18-74

Enrollment Opens: 03-21-2022

Enrollment Closes: TBD

More info »